Sodium polystyrene sulfonate: Difference between revisions
ClaireLewis (talk | contribs) No edit summary |
|||
(One intermediate revision by one other user not shown) | |||
Line 2: | Line 2: | ||
*Type: | *Type: | ||
*Dosage Forms: | *Dosage Forms: | ||
*Common Trade Names: | *Common Trade Names: Kayexalate | ||
==Adult Dosing== | ==Adult Dosing== | ||
Line 46: | Line 46: | ||
==See Also== | ==See Also== | ||
*Alternative [[Sodium zirconium cyclosilicate]] (Lokelma) | |||
==References== | ==References== |
Latest revision as of 09:30, 16 January 2021
General
- Type:
- Dosage Forms:
- Common Trade Names: Kayexalate
Adult Dosing
Hyperkalemia
- 30 gm oral or per rectum
Pediatric Dosing
- >1mo: 1 g/kg PO or PR q6hr PRN
Special Populations
- Pregnancy Rating: B
- Lactation: Not absorbed systemically so infant risk minimal
- Renal Dosing
- Adult
- Pediatric
- Hepatic Dosing
- Adult
- Pediatric
Contraindications
- Allergy to class/drug
- Hypokalemia
- Obstructive bowel disease, reduced gut motility
- Rectal administration in neonates, particularly if premature
Adverse Reactions
Serious
- Intestinal necrosis, ulceration, perforation, fecal impaction
- Bezoars
Common
- Abdominal pain, nausea/vomiting, constipation, GI disturbance
- Hypokalemia
- Hypocalcemia
- Hypomagnesemia
- Sodium retention
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
- Mechanism of Action: Cation exchange resin, sodium ions partially released from polystyrene and replaced by potassium
See Also
- Alternative Sodium zirconium cyclosilicate (Lokelma)